Biocentury This Week Looks at Venture Capital

No one doubts the venture capital world is shrinking for life sciences.

But at least 345 venture stage biotechs around the world closed VC deals worth more than $6 billion last year. It was the second highest total in the past decade. And the total has not fallen below $5 billion in that time.

How has this happened? One answer: Corporate venture capital stepped in to fill the breach. This means big pharmaceutical and biotech companies are partnering with traditional VCs to invest in biotechs offering potential breakthrough technologies and products.

Can this ecosystem sustain the flow of innovation into the marketplace?


BioCentury 02.17.13 - [1] Pharma Steps In


BioCentury speaks with:

Kurt   von Emster   of the $200 million VenBio fund, which combines traditional limited partners   with strategic investors like Amgen and Abbott.
Carole   Nuechterlein,   head of the $500 million Roche Venture Fund.


NOTICE:   BioCentury Publications, Inc., and WUSA-TV own the copyright to the program content on “BioCentury This Week,” and except for limited use of these links to the website, BioCentury and WUSA prohibit hosting of BioCentury This Week program content by unauthorized third parties or posting of BioCentury This Week content to any unauthorized third party websites such as YouTube. Other content and all trademarks are the property of BioCentury or WUSA-TV or other third parties.
Posted in AZBio News.